

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

16 Sep 2026

### The effect of low dose Dexmedetomidine in reducing the dose of analgesic and sedative medications in the pediatric intensive care unit

#### Protocol summary

##### Study aim

Evaluation of efficacy and safety of low dose dexmedetomidine in reducing the dose of analgesic and sedative medications in the pediatric intensive care unit

##### Design

A phase three, randomized, parallel-group clinical trial with blinded intervention and outcome assessment. Randomization was centralized and computerized with a concealed randomization sequence carried out at <https://www.sealedenvelope.com/>.

##### Settings and conduct

Sixty children from one year to 12 years old who are hospitalized in the special care department of the hospital and need mechanical ventilation and sedation are examined. The patients will be divided into two groups, and a drug package with a unique code will be delivered to them. The patient, the caregiver, and the investigator will be blind to the package content.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Age 1 year to 12 years, Admission to pediatric intensive care unit ,under mechanical ventilation and sedation Exclusion criteria: Children receiving Barbiturates, Persistent bradycardia, Hypotension, Cardiac arrhythmia, Involvement of the central nervous system.

##### Intervention groups

The control group consists of 30 patients and will be anesthetized with 0.1 milligrams per kilogram of intravenous Midazolam and 1 (or more) microgram per kilogram of Fentanyl and placebo. The intervention group consists of 30 patients and will be anesthetized with 0.1 milligram per kilogram intravenous Midazolam and 1 (or more) microgram per kilogram of Fentanyl along with 0.5 microgram per kilogram per hour Dexmedomidine

##### Main outcome variables

The reduction of Midazolam and Fentanyl dose.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20230520058235N1**

Registration date: **2023-07-23, 1402/05/01**

Registration timing: **prospective**

Last update: **2023-07-23, 1402/05/01**

Update count: **0**

##### Registration date

2023-07-23, 1402/05/01

##### Registrant information

##### Name

Najmeh Forouzan

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8892 6571

##### Email address

negar.iker@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-08-23, 1402/06/01

##### Expected recruitment end date

2024-08-22, 1403/06/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

The effect of low dose Dexmedetomidine in reducing the dose of analgesic and sedative medications in the pediatric intensive care unit

**Public title**

Effect of Dexmedetomidine in pediatric anesthesia

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Age 1 year to 12 years Admission to pediatric intensive care unit (PICU) Under mechanical ventilation and sedation

**Exclusion criteria:**

Children receiving Barbiturates Persistent bradycardia (less than 5th percentile of normal for age) Hypotension (less than 5th percentile of normal age) Cardiac arrhythmia Involvement of the central nervous system (brain trauma, encephalitis, meningitis...)

**Age**

From **1 year** old to **12 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Data analyser

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

The randomization has been performed using the block randomization table. The block randomization method is designed to randomize subjects into ten blocks consisting of six and four patients resulting in two equally divided groups. This method is used to ensure a balance in sample size across groups over time. Randomization was centralized and computerized with a concealed randomization sequence carried out at <https://www.sealedenvelope.com/>. In this method, a randomization list with unique codes for each patient is generated. Patients will enroll in the study based on the randomization list into medication or placebo groups with a unique code for follow-up. The allocation person will inform the investigators of the patient codes from the list by phone for randomization and blinding.

**Blinding (investigator's opinion)**

Triple blinded

**Blinding description**

The drug and placebo will be in coded same packages; a designated person will provide the codes from block randomization via phone. The same person will group the data at the end of the trial, and the expert will perform statistical analysis and after results, the pocket that is with the placebo provider would be opened, and the data will be decrypted. The data regarding harm and benefits of treatment will be provided to the patient and caregiver.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Research Ethics Committees of School of Pharmacy and Nursing & Midwifery- Shahid Beheshti University

**Street address**

2nd floor, School of Nursing and Midwifery, Valiasr and Niayesh junction

**City**

Tehran

**Province**

Tehran

**Postal code**

1546815514

**Approval date**

2023-06-20, 1402/03/30

**Ethics committee reference number**

IR.SBMU.PHARMACY.REC.1402.066

**Health conditions studied****1****Description of health condition studied**

Opioid related disorders in pediatric intensive care unit

**ICD-10 code**

F11

**ICD-10 code description**

Opioid related disorders

**Primary outcomes****1****Description**

Determining and comparing the needed total Fentanyl dose in each group

**Timepoint**

From enrollment up to seven days

**Method of measurement**

Dose counting

**2****Description**

Determining and comparing the needed total Midazolam dose in each group

**Timepoint**

From enrollment up to seven days

**Method of measurement**

Dose counting

**Secondary outcomes****1****Description**

Determining the need for a second sedative drug in each group

**Timepoint**

From enrollment up to seven days

**Method of measurement**

Patient file

**2****Description**

Determining the need for the third sedative drug in each group

**Timepoint**

From enrollment up to seven days

**Method of measurement**

Patient file

**3****Description**

Determining the need for the muscle relaxant in each group

**Timepoint**

From enrollment up to seven days

**Method of measurement**

Patient file

**Intervention groups****1****Description**

Intervention group: In this group, patients will be anesthetized with 0.1 milligram per kilogram of intravenous Midazolam and 1 (or more) micrograms per kilogram of Fentanyl along with 0.2 micrograms per kilogram per hour of Dexmedomidine.

**Category**

Treatment - Drugs

**2****Description**

Control group: In this group, they will be anesthetized with 0.1 milligram of intravenous Midazolam per kilogram and 1 (or more) micrograms of Fentanyl per kilogram.

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Mofid children's Hospital

**Full name of responsible person**

Bahador Mirrahimi

**Street address**

Mofid Children's Hospital, Mirdamad Junction, Shariaty Ave.

**City**

Tehran

**Province**

Tehran

**Postal code**

1546815514

**Phone**

+98 21 2222 7029

**Email**

mirrahimi@sbmu.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Dr. Seyed Ali Ziaee

**Street address**

3rd Floor, Faculty of medicine, Arabi Ave, Daneshjoo Blvd, Velenjak

**City**

Tehran

**Province**

Tehran

**Postal code**

1991953381

**Phone**

+98 21 2243 9951

**Email**

mpd@sbmu.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Najmeh Forouzan

**Position**

Clinical Pharmacy Resident

**Latest degree**

Specialist

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

School of Pharmacy, Shahid Beheshti University of Medical Sciences, Niayesh Highway, Valiasr Ave, Tehran, Iran.

**City**

Tehran

**Province**

Tehran

**Postal code**

1985717443

**Phone**

+98 21 2222 7020

**Email**

najmeh.star@ymail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Dr. Bahador Mirrahimi

**Position**

Assistant Professor, Pharmacotherapy.

**Latest degree**

Specialist

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Mofid children's Hospital, Miradmad Junction, Shariaty Ave.

**City**

Tehran

**Province**

Tehran

**Postal code**

1991953381

**Phone**

+98 21 2222 7020

**Email**

mirrahimi@sbmu.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Najmeh Forouzan

**Position**

Clinical Pharmacy Resident

**Latest degree**

Specialist

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

School of Pharmacy, Shahid Beheshti University of Medical Sciences, Niayesh Highway, Valiasr Ave, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1985717443

**Phone**

+98 21 2222 7020

**Email**

najmeh.star@ymail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

The main outcome will be available.

**When the data will become available and for how long**

Six months after publishing data.

**To whom data/document is available**

The data will be available per request for people working in academic institutions.

**Under which criteria data/document could be used**

The data will be available for using in systematic review and meta-analysis.

**From where data/document is obtainable**

The data will be available by contacting email; mirrahimi@sbmu.ac.ir.

**What processes are involved for a request to access data/document**

The data will be available for using in systematic review and meta-analysis.

**Comments**